| __timestamp | Regeneron Pharmaceuticals, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 1213000 |
| Thursday, January 1, 2015 | 838526000 | 3425000 |
| Friday, January 1, 2016 | 1177697000 | 6311000 |
| Sunday, January 1, 2017 | 1320433000 | 9518000 |
| Monday, January 1, 2018 | 1556200000 | 28080000 |
| Tuesday, January 1, 2019 | 1834800000 | 36550000 |
| Wednesday, January 1, 2020 | 1346000000 | 46125000 |
| Friday, January 1, 2021 | 1824900000 | 68486000 |
| Saturday, January 1, 2022 | 2115900000 | 92032000 |
| Sunday, January 1, 2023 | 2631300000 | 117532000 |
| Monday, January 1, 2024 | 2954400000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. From 2014 to 2023, Regeneron Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have shown contrasting trajectories in their SG&A expenditures. Regeneron, a leader in biotechnology, saw its SG&A costs rise by over 400%, peaking in 2023. This reflects its aggressive expansion and investment in new therapies. Meanwhile, Rhythm Pharmaceuticals, a smaller player, experienced a staggering 9,600% increase in SG&A expenses, indicating its rapid scaling efforts. By 2023, Regeneron's SG&A expenses were approximately 22 times higher than Rhythm's, highlighting the disparity in their operational scales. This data underscores the dynamic nature of the pharmaceutical industry, where strategic financial management can dictate a company's market position.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
argenx SE and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Incyte Corporation and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Perrigo Company plc Trends and Insights
Rhythm Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or Xencor, Inc.